Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
REACT-IrNPC
Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
- NCT04448522 ↗
- Recruiting
- Sun Yat-sen University
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on REACT-IrNPC (chemotherapy-sensitive stage II-III nasopharyngeal carcinoma; tests no drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REACT-IrNPC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Multicenter Randomized Controlled Trial Comparing Reduced Dose With Regular Dose Intensity-modulated Radiotherapy for Chemotherapy Sensitive Stage II-III Nasopharyngeal Carcinoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Nasopharyngeal Carcinoma; Radiotherapy; Chemotherapy
- Interventions
- reduced dosage IMRT; conventional dosage IMRT
- Arms
- Reduced dosage IMRT group · Experimental
- Conventional dosage IMRT group · Active comparator
- Enrollment
- 508 (estimated)
- Primary outcomes
- Progress-free survival (PFS)
- Sponsor
- Sun Yat-sen University with National Cancer Centre, Singapore, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhongshan People's Hospital, Guangdong, China, Yuebei People's Hospital, Wuzhou Red Cross Hospital
- Start
- Aug 18, 2020
- Primary completion
- Aug 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04448522 · updated Sep 28, 2020